7 unknown. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
| Phase 1 | 2 | Unknown 2 |
Follow Safety Issues: new trials by email Literature Review of Safety Issues trials Research Report on Safety Issues
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen - Efficacy, Self, Safety Issues | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 72 | 2024-07-01 | 2024-07-09 |
| Is Local Injection of Mesenchymal Stem Cells After Endoscopic Dilation Safe and Does it Improve the Outcome of Intestinal Stricture in Patients With Crohn's Disease? Mesenchymal Stem Cells, Comparative placebo - Safety Issues, Efficacy | Phase 2 | Unknown | Centre Hospitalier Universitaire de Liege | 50 | 2023-06-06 | 2024-03-19 |
| Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma low dose nivolumab in combination with AVD - Safety Issues, Efficacy, Self | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 16 | 2023-02-13 | 2023-03-16 |
| Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma Sintilimab 200mg+MB07133 600mg - Safety Issues, Efficacy | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 39 | 2022-01-18 | 2023-11-21 |
| TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss TQB3525 - Safety Issues, Efficacy, Self | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 29 | 2020-10-01 | 2020-12-31 |
| MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma MB07133 - Safety Issues, Effect of Drug | Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 91 | 2020-01-17 | 2023-11-21 |
| Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer Atezolizumab - Safety Issues | Phase 2 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 25 | 2018-05-01 | 2018-08-13 |
Chondrosarcoma (1) · Colonic Neoplasms (1) · Hodgkin Disease (1) · Osteosarcoma (1) · Sarcoma, Ewing (1)
Neoplasms (3) · Neoplasms by Histologic Type (2) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Lymphatic Diseases (1) · Lymphoma (1)
4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (2) · Nivolumab (1) · TQ-B3525 (1) · atezolizumab (1) · sintilimab (1)
Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Centre Hospitalier Universitaire de Liege (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Peking University People's Hospital (1) · Sir Run Run Shaw Hospital (1)
China (4) · Belgium (1) · Canada (1) · Mexico (1)
Perla R Colunga Pedraza, MD (1) · Wassim Kassouf, MD (1) · Wei Guo, Ph.D and M.D. (1)
PMID 28434018, PMID 31112476, PMID 32352505, PMID 32786092, PMID 33062947